Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) shares gapped up prior to trading on Tuesday . The stock had previously closed at $6.49, but opened at $6.78. Iovance Biotherapeutics shares last traded at $6.27, with a volume of 27,858 shares changing hands.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on IOVA. Wells Fargo & Company restated an “equal weight” rating and issued a $14.00 price target on shares of Iovance Biotherapeutics in a research note on Thursday, August 18th. Guggenheim began coverage on Iovance Biotherapeutics in a report on Monday, October 31st. They issued a “neutral” rating for the company. Oppenheimer dropped their price objective on Iovance Biotherapeutics from $27.00 to $25.00 in a report on Friday, November 18th. StockNews.com began coverage on Iovance Biotherapeutics in a report on Wednesday, October 12th. They issued a “sell” rating for the company. Finally, Piper Sandler dropped their price objective on Iovance Biotherapeutics from $13.00 to $11.00 and set a “neutral” rating for the company in a report on Sunday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.40.
Iovance Biotherapeutics Stock Performance
The company has a market cap of $981.77 million, a price-to-earnings ratio of -2.52 and a beta of 0.50. The business has a fifty day moving average price of $9.04 and a 200 day moving average price of $10.53.
Hedge Funds Weigh In On Iovance Biotherapeutics
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.